GlassScriptPhysician profile
Helen C Ly
NPI 1487882627
$8,527.06
in general payments reported to CMS, 2019-2025
40 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $1,108 · 2021: $1,502 · 2022: $1,867 · 2023: $1,091 · 2024: $632 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,902.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,637.31 | 2021-2025 | |
| Amgen INC. | $668.74 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $666.85 | 2019-2025 | Emgality, Amyvid |
| Teva Pharmaceuticals USA, INC. | $628.08 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Amneal Pharmaceuticals LLC | $566.67 | 2019-2025 | Ongentys, Crexont, Rytary |
| Eisai INC. | $536.67 | 2019-2023 | |
| Upsher-Smith Laboratories LLC | $471.77 | 2019-2023 | |
| Allergan, INC. | $393.48 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $307.97 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $278.93 | 2020-2021 | |
| Pfizer INC. | $277.66 | 2021-2025 | |
| Genzyme Corporation | $188.14 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $173.70 | 2020-2021 | |
| Genentech USA, INC. | $155.89 | 2019-2025 | Ocrevus Zunovo |
| C2n Diagnostics, LLC | $135.21 | 2025 | Precivityad2 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.